ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › Biomarker Validation
Regulatory

Biomarker Validation

The rigorous process of proving a biomarker's {{clinical-utility|clinical utility}}–the path from discovery to diagnostic.

View
Definition
Biomarker validation is the systematic demonstration that a biomarker assay is fit for its intended clinical purpose. This encompasses three levels: analytical validity (the assay accurately measures the biomarker), clinical validity (the biomarker correlates with clinical outcomes), and clinical utilityLoading... (biomarker-guided decisions improve patient outcomes). Regulatory approval as a companion diagnosticLoading... requires rigorous demonstration of all three.
Video Segments
JCO Clinical Study: 188 NSCLC Patients
Primary
Antibody QC & Clone Selection
Primary
Related Segments
Drug Dose-Response by FRET
Related
Analytical Validity
Accurate measurement
Clinical Validity
Outcome correlation
{{clinical-utility|clinical utility}}
Improved decisions
Regulatory Path
FDA/CE approval

The Three Pillars

Analytical validity asks: does the assay measure what it claims? For iFRETLoading..., this means demonstrating that FRET efficiency accurately reflects protein-protein proximity, with appropriate precision, reproducibility, and robustness.

Clinical validity asks: does the biomarker correlate with outcomes? The PD-1/PD-L1 iFRET studies demonstrating p=0.05 survival correlation (vs. p=0.87 for expression) establish clinical validity.

clinical utilityLoading... asks: do biomarker-guided decisions improve outcomes? This requires prospective interventional trials showing that using the biomarker leads to better patient outcomes than standard care.

Simplified

Three Questions Must Be Answered:

1. Does it measure what we claim? (Analytical validity)

2. Does it correlate with patient outcomes? (Clinical validity)

3. Do patients do better when we use it to guide treatment? (clinical utilityLoading...)

Only after answering all three can a biomarker become a standard diagnostic test.

The Functional Biomarker Evidence Base

FRETLoading...-based functional biomarkersLoading... have demonstrated analytical validity through decades of biophysical characterization–the physics is well-established. Clinical validity has been demonstrated across multiple studies: Akt activationLoading... in breast cancerLoading... (2014), PKB/Akt in ccRCCLoading... (2017), PD-1/PD-L1Loading... engagement (2020), and others.

The path to clinical utilityLoading... requires prospective trials. Ongoing collaborations, including the HAWK/OSU melanomaLoading... study, are building this evidence base.

Simplified

Where QF-Pro Stands:

• Analytical validity: Established—FRET physics is well-understood

• Clinical validity: Demonstrated in multiple studies (PD-1/PD-L1 survival correlation P=0.05, Akt activation in breast and kidney cancer)

• clinical utilityLoading...: Being investigated in ongoing prospective trials

QF-Pro Validation Status

Clinically Validated

Evidence Summary:
• Analytical: FRET efficiency validated across tissue types
• Clinical: PD-1/PD-L1 (n=176[3], P=0.05[3]), PKB/Akt (n=164[1]+60, P<0.05[1,2])

clinical utilityLoading... requires prospective trials. The HAWK/OSU melanoma collaboration represents ongoing investigation.

Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...

Simplified

Validation status: Analytically validated across tissue types. Clinically validated in 400+ patients across multiple cancer types. Ongoing prospective trials with HAWK/OSU collaboration.

Regulatory Pathway

  • Presubmission meetings: Early FDA engagement on validation strategy
  • Analytical studies: Precision, accuracy, reproducibility, lot-to-lot consistency
  • Clinical studies: Retrospective validation, then prospective confirmation
  • Co-development: Parallel development with therapeutic for companion diagnosticLoading... status

Connected Terms

Share This Term
Term Connections